Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) EBT (2016 - 2025)

Historic EBT for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to -$32.9 million.

  • Standard Biotools' EBT fell 5091.05% to -$32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$152.2 million, marking a year-over-year decrease of 5345.1%. This contributed to the annual value of -$138.3 million for FY2024, which is 8639.43% down from last year.
  • Latest data reveals that Standard Biotools reported EBT of -$32.9 million as of Q3 2025, which was down 5091.05% from -$18.3 million recorded in Q2 2025.
  • Standard Biotools' 5-year EBT high stood at -$10.2 million for Q4 2021, and its period low was -$76.9 million during Q1 2022.
  • Over the past 5 years, Standard Biotools' median EBT value was -$20.9 million (recorded in 2023), while the average stood at -$29.6 million.
  • As far as peak fluctuations go, Standard Biotools' EBT soared by 7842.89% in 2023, and later crashed by 27524.33% in 2024.
  • Over the past 5 years, Standard Biotools' EBT (Quarter) stood at -$10.2 million in 2021, then plummeted by 102.82% to -$20.8 million in 2022, then increased by 4.03% to -$19.9 million in 2023, then tumbled by 275.24% to -$74.8 million in 2024, then skyrocketed by 56.03% to -$32.9 million in 2025.
  • Its EBT was -$32.9 million in Q3 2025, compared to -$18.3 million in Q2 2025 and -$26.2 million in Q1 2025.